Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials

Overview

Journal Drugs

Specialty Pharmacology

Date 2024 Mar 13

PMID 38478331

Authors

Yifan Wang

He Yi

Weixia Sun

Hekai Yu

Wenxuan Tao

Xiaojin Yu

Dianrong Jia

Yingzhao Liu

Stephen J Pandol

Ling Li

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Nonalcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), affects approximately 38% of the world's population, yet no pharmacological therapies have been approved for treatment. We conducted a traditional and network meta-analysis to comprehensively assess the effectiveness of drug regimens on NAFLD, and continued to use the old terminology for consistency.

Methods: Randomized, placebo-controlled trials (RCTs) investigating drug therapy in an adult population diagnosed with NAFLD with or without diabetes mellitus were included. We assessed the quality of RCTs via the Risk of Bias 2 (ROB 2) tool. When I < 50%, we chose a random-effects model, otherwise a fixed-effects model was selected. A random effects model was applied in the network meta-analysis. The odds ratio (OR), weighted mean difference (WMD) or standard mean difference (SMD) with 95% confidence interval (CI) were used for outcome evaluation. The primary endpoint was the resolution of nonalcoholic steatohepatitis (NASH) without the worsening of liver fibrosis. Other endpoints included histological findings and metabolic changes. The PROSPERO Registration ID was CRD42023404309.

Results: Thiazolidinediones (TZDs), vitamin E plus pioglitazone, glucagon-like peptide-1 (GLP-1) receptor agonists and fibroblast growth factor-21 (FGF-21) analogue had a higher surface under the cumulative ranking curve (SUCRA = 76.6, 73.0, 72.0 and 71.6) regarding NASH resolution. Improvement of liver fibrosis stage (≥ 1) was observed with obeticholic acid 25 mg/day (OR 2.01, 95% CI 1.35-2.98), lanifibranor 1200 mg/day (OR 2.39, 95% CI 1.19-4.82) and silymarin (OR 4.54, 95% CI 1.18-17.43) in traditional meta-analysis.

Conclusions: The results of the comprehensive analysis suggested hypoglycemic drug therapy as an effective intervention for NAFLD, with or without diabetes mellitus. A prioritized selection of TZDs, vitamin E plus pioglitazone, GLP-1 receptor agonists and FGF-21 analogue may be considered for NASH resolution. Obeticholic acid, lanifibranor and silymarin could be considered for the improvement of liver fibrosis. Each medication was relatively safe compared with placebo.

References

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Wong V, Ekstedt M, Wong G, Hagstrom H . Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023; 79(3):842-852. DOI: 10.1016/j.jhep.2023.04.036. View

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.003. View

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Friedman S, Neuschwander-Tetri B, Rinella M, Sanyal A . Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24(7):908-922. PMC: 6553468. DOI: 10.1038/s41591-018-0104-9. View

Stefan N, Cusi K . A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022; 10(4):284-296. DOI: 10.1016/S2213-8587(22)00003-1. View

Shi J, Luo D, Weng H, Zeng X, Lin L, Chu H . Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020; 11(5):641-654. DOI: 10.1002/jrsm.1429. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Newsome P, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V . A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2020; 384(12):1113-1124. DOI: 10.1056/NEJMoa2028395. View

10.

Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Sundby Palle M . Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021; 54(9):1150-1161. PMC: 9292692. DOI: 10.1111/apt.16608. View

11.

Armstrong M, Gaunt P, Aithal G, Barton D, Hull D, Parker R . Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2015; 387(10019):679-690. DOI: 10.1016/S0140-6736(15)00803-X. View

12.

Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L . Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135(1):100-10. DOI: 10.1053/j.gastro.2008.03.078. View

13.

Aithal G, Thomas J, Kaye P, Lawson A, Ryder S, Spendlove I . Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4):1176-84. DOI: 10.1053/j.gastro.2008.06.047. View

14.

Balas B, Belfort R, Harrison S, Darland C, Finch J, Schenker S . Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol. 2007; 47(4):565-70. DOI: 10.1016/j.jhep.2007.04.013. View

15.

Belfort R, Harrison S, Brown K, Darland C, Finch J, Hardies J . A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22):2297-307. DOI: 10.1056/NEJMoa060326. View

16.

Huang J, Dai C, Huang C, Tsai P, Yeh M, Hsu P . First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. Hepatol Int. 2021; 15(5):1136-1147. DOI: 10.1007/s12072-021-10242-2. View

17.

Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C . Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016; 165(5):305-15. DOI: 10.7326/M15-1774. View

18.

Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Babaei M . Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther. 2020; 37(11):4697-4708. PMC: 7547956. DOI: 10.1007/s12325-020-01498-5. View

19.

Joy T, McKenzie C, Tirona R, Summers K, Seney S, Chakrabarti S . Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. World J Gastroenterol. 2017; 23(1):141-150. PMC: 5221278. DOI: 10.3748/wjg.v23.i1.141. View

20.

Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R . Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol. 2016; 65(2):369-76. PMC: 5081213. DOI: 10.1016/j.jhep.2016.04.021. View